Seth M. Pollack, MD

A pilot early phase 1 trial (NCT07261657) represents the first clinical effort to activate persisting transferred rare persisting cells by using IL-15 superagonist N-803.

Seth M. Pollack, MD, discussed how the ECOG-ACRIN EA7222 trial could establish doxorubicin/pembrolizumab as the new frontline standard for undifferentiated pleomorphic sarcoma.

Seth M. Pollack, MD, discusses new strategies for converting immune-cold tumors, including the role of TLR4 agonists and IL-12–producing viral agents.